Equities
Health CareHealth Care Equipment & Services
  • Price (EUR)1.22
  • Today's Change-0.037 / -2.94%
  • Shares traded22.89k
  • 1 Year change-42.91%
  • Beta0.6563
Data delayed at least 15 minutes, as of Sep 26 2016 14:28 BST.
More ▼

Profile data is unavailable for this security.

About the company

aap Implantate AG is a Germany-based provider of medical devices for human muscular and skeletal systems. The Company focuses on trauma and biomaterials products for orthopedics. The Biomaterials portfolio comprises bone substitutes for the filling of aseptic bone defects, bone cements and accessories for the application in arthroplasty, bone cements and accessories for the application in vertebroplasty and kyphoplasty. The trauma portfolio includes a wide range of cannulated screws, standard plates and screws for miniature, small and large bone fragments, among others . It also develops LOQTEQ, a technology that allows for fracture compression with subsequent locking fixation in one surgical step. The Company operates a network of distributors in more than 60 countries, and cooperates directly with physicians and hospital customers.

  • Revenue in EUR (TTM)11.74m
  • Net income in EUR-10.61m
  • Incorporated--
  • Employees172.00
  • Location
    Aap Implantate AGLorenzweg 5BERLIN 12099GermanyDEU
  • Phone+49 30750190Fax+49 3 075019111
  • Websitehttp://www.aap.de/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Bio Gate AG3.55m-251.42k8.66m22.008.66m22.00
Medisana AG59.30m66.64k26.97m157.0026.97m157.00
aap Implantate AG11.74m-10.61m38.63m172.0038.63m172.00
Geratherm Medical AG22.26m2.63m58.58m204.0058.58m204.00
MagForce AG2.58m-1.55m109.56m25.00109.56m25.00
Data as of Sep 26 2016. Currency figures normalised to Aap Implantate AG's reporting currency: Euro EUR
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.